Sudan Loganathan
Stock Analyst at Stephens & Co.
(3.78)
# 657
Out of 5,148 analysts
46
Total ratings
56.41%
Success rate
8.97%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Sudan Loganathan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KYMR Kymera Therapeutics | Maintains: Overweight | $95 → $100 | $88.00 | +13.64% | 4 | Mar 2, 2026 | |
| APGE Apogee Therapeutics | Initiates: Overweight | $95 | $67.01 | +41.77% | 1 | Dec 17, 2025 | |
| CADL Candel Therapeutics | Reiterates: Overweight | $15 | $4.93 | +204.26% | 2 | Dec 8, 2025 | |
| PYXS Pyxis Oncology | Maintains: Overweight | $5 → $8 | $1.44 | +457.49% | 2 | Nov 24, 2025 | |
| IMNM Immunome | Maintains: Overweight | $25 → $33 | $21.57 | +52.99% | 3 | Nov 17, 2025 | |
| ARVN Arvinas | Maintains: Overweight | $14 → $15 | $13.17 | +13.90% | 3 | Nov 10, 2025 | |
| DCTH Delcath Systems | Maintains: Overweight | $25 → $18 | $8.71 | +106.66% | 4 | Nov 5, 2025 | |
| CNTA Centessa Pharmaceuticals | Initiates: Overweight | $35 | $25.85 | +35.40% | 1 | Oct 28, 2025 | |
| CCCC C4 Therapeutics | Reiterates: Overweight | $6 | $2.97 | +102.02% | 3 | Sep 22, 2025 | |
| IDYA IDEAYA Biosciences | Reiterates: Overweight | $45 | $34.81 | +29.27% | 3 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $30 | $15.35 | +95.44% | 4 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $29 → $60 | $40.65 | +47.60% | 5 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $33 | $23.95 | +37.79% | 2 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $8 | $4.02 | +99.00% | 2 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $15 | $5.53 | +171.25% | 2 | Jan 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $1.11 | +350.45% | 2 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $100 | $28.56 | +250.14% | 2 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.71 | +1,073.02% | 1 | May 14, 2024 |
Kymera Therapeutics
Mar 2, 2026
Maintains: Overweight
Price Target: $95 → $100
Current: $88.00
Upside: +13.64%
Apogee Therapeutics
Dec 17, 2025
Initiates: Overweight
Price Target: $95
Current: $67.01
Upside: +41.77%
Candel Therapeutics
Dec 8, 2025
Reiterates: Overweight
Price Target: $15
Current: $4.93
Upside: +204.26%
Pyxis Oncology
Nov 24, 2025
Maintains: Overweight
Price Target: $5 → $8
Current: $1.44
Upside: +457.49%
Immunome
Nov 17, 2025
Maintains: Overweight
Price Target: $25 → $33
Current: $21.57
Upside: +52.99%
Arvinas
Nov 10, 2025
Maintains: Overweight
Price Target: $14 → $15
Current: $13.17
Upside: +13.90%
Delcath Systems
Nov 5, 2025
Maintains: Overweight
Price Target: $25 → $18
Current: $8.71
Upside: +106.66%
Centessa Pharmaceuticals
Oct 28, 2025
Initiates: Overweight
Price Target: $35
Current: $25.85
Upside: +35.40%
C4 Therapeutics
Sep 22, 2025
Reiterates: Overweight
Price Target: $6
Current: $2.97
Upside: +102.02%
IDEAYA Biosciences
Sep 9, 2025
Reiterates: Overweight
Price Target: $45
Current: $34.81
Upside: +29.27%
Jul 10, 2025
Reiterates: Overweight
Price Target: $30
Current: $15.35
Upside: +95.44%
Jun 24, 2025
Upgrades: Overweight
Price Target: $29 → $60
Current: $40.65
Upside: +47.60%
Feb 27, 2025
Reiterates: Overweight
Price Target: $33
Current: $23.95
Upside: +37.79%
Feb 24, 2025
Maintains: Overweight
Price Target: $6 → $8
Current: $4.02
Upside: +99.00%
Jan 22, 2025
Reiterates: Equal-Weight
Price Target: $15
Current: $5.53
Upside: +171.25%
Nov 19, 2024
Reiterates: Overweight
Price Target: $5
Current: $1.11
Upside: +350.45%
May 24, 2024
Reiterates: Overweight
Price Target: $100
Current: $28.56
Upside: +250.14%
May 14, 2024
Initiates: Overweight
Price Target: $20
Current: $1.71
Upside: +1,073.02%